Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
230,6 USD | +0,23% | +4,09% | -10,90% |
Attività
- vendite di farmaci (73,7%): per il trattamento della sclerosi multipla, della psoriasi cronica negli adulti, dell'artrite reumatoide, dei tumori, ecc;
- royalties (17,2%) ;
- altro (9,1%): principalmente ricavi da accordi di partnership.
Numero di dipendenti: 7 570
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 10 173 | 100,0 % | 9 836 | 100,0 % | -3,32% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
55,2
%
| 5 532 | 54,4 % | 5 434 | 55,2 % | -1,77% |
Europe
21,8
%
| 2 413 | 23,7 % | 2 140 | 21,8 % | -11,34% |
Germany
8,8
%
| 926 | 9,1 % | 868 | 8,8 % | -6,28% |
Asia
8,8
%
| 720 | 7,1 % | 863 | 8,8 % | +19,97% |
Other
5,4
%
| 583 | 5,7 % | 531 | 5,4 % | -8,87% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Chief Executive Officer | 64 | 14/11/22 | |
Director of Finance/CFO | 60 | 15/08/20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 01/01/15 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 57 | 02/10/23 |
Chuck Triano
IRC | Investor Relations Contact | - | 10/04/23 |
Michael Hencke
IRO | Public Communications Contact | - | 01/07/12 |
Michael Dambach
TRE | Treasurer | 57 | 01/01/07 |
Corporate Secretary | - | - | |
Robert Kilo
PRN | Corporate Officer/Principal | - | - |
Rachid Izzar
PRN | Corporate Officer/Principal | - | 01/01/21 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01/01/10 |
William Hawkins
BRD | Director/Board Member | 70 | 19/06/19 |
Caroline Dorsa
CHM | Chairman | 64 | 03/01/10 |
Eric Rowinsky
BRD | Director/Board Member | 67 | 20/03/10 |
Chief Executive Officer | 64 | 14/11/22 | |
Maria Freire
BRD | Director/Board Member | 69 | 02/06/21 |
Director/Board Member | 54 | 01/01 | |
Jesus Mantas
BRD | Director/Board Member | 55 | 19/06/19 |
Susan Langer
BRD | Director/Board Member | - | 26/06/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 169 396 895 | 145 366 956 ( 85,81 %) | 23 800 000 ( 14,05 %) | 85,81 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
DENALI THERAPEUTICS INC. 8.95% | 12 751 365 | 8.95% | 190 760 420 $ |
SAGE THERAPEUTICS, INC. 10.38% | 6 241 473 | 10.38% | 84 759 203 $ |
14 652 466 | 7.19% | 7 370 190 $ |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. |
Biotechnology
|
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. |
Pharmaceuticals: Major
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-10,90% | 33,57 Mrd | |
-2,32% | 90,45 Mrd | |
+3,68% | 41,45 Mrd | |
+58,05% | 25,73 Mrd | |
-19,56% | 14,73 Mrd | |
-9,06% | 12,82 Mrd | |
-11,34% | 11,7 Mrd | |
-43,53% | 11,44 Mrd | |
+3,75% | 8,79 Mrd | |
-6,32% | 8,35 Mrd |
- Borsa valori
- Azioni
- Azione BIIB
- Società Biogen Inc.